The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC.
Simple Summary: EGFR adjusted variant allele frequency (aVAF) is a molecular testing metric postulated to reflect how much of a tumor is made up of cells carrying the EGFR mutation. In this study, we examined whether EGFR aVAF was associated with outcomes in patients with advanced EGFR-mutant NSCLC...
| Publicado en: | Current Oncology Vol. 33; no. 8; pp. 439 - 449 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Aug2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196621266&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 196621266 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Aug2026 vid: 33 iid: 8 pid: 97109 pub: MDPI artinfo: ui: 196621266 10.3390/curroncol33080439 196621266 ppf: 439 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: The Prognostic Significance of EGFR Adjusted Variant Allele Frequency on First-Line Osimertinib Efficacy in Advanced EGFR-Mutant NSCLC. aug: au: Phillips, William J. Leong, Russell Yeung, Benjamin Al Lawati, Ahmed Camidge, D. Ross Lo, Bryan Wheatley-Price, Paul affil: University of Colorado Cancer Center, Aurora, CO 80045, USA sug: ab: Simple Summary: EGFR adjusted variant allele frequency (aVAF) is a molecular testing metric postulated to reflect how much of a tumor is made up of cells carrying the EGFR mutation. In this study, we examined whether EGFR aVAF was associated with outcomes in patients with advanced EGFR-mutant NSCLC treated with first-line osimertinib. We found that patients had similar progression-free survival and overall survival regardless of their tumor's EGFR aVAF value, suggesting that it is unlikely to be useful for predicting outcomes, although larger studies are needed to verify these findings. Introduction: The prognostic significance of EGFR variant allele frequency (VAF) remains unclear in advanced EGFR-mutant (EGFR-mt) NSCLC. We examined the relationship of EGFR VAF and clinical outcomes in patients treated with first-line osimertinib. Methods: This retrospective cohort study evaluated patients with advanced EGFR-mt NSCLC treated at the Ottawa Hospital between July 2021 and June 2023. Baseline characteristics were collected from electronic medical records. Adjusted VAF (aVAF) was calculated by normalizing EGFR VAF to tumor cellularity and analyzed according to predefined thresholds: aVAF < 50% (low) and aVAF > 100% (high). The primary outcome was progression-free survival (PFS). Results: Of 141 patients diagnosed with EGFR-mt NSCLC, 59 were included. The median age was 70 years, and 70% were females. There were 23 (39.0%) cases with low aVAF and 16 (27.1%) with high aVAF. Neither aVAF < 50% (HR = 1.01; p = 0.76) or aVAF > 100% (HR = 0.81; p = 0.57) was associated with PFS. However, ECOG performance status ≥ 2 (vs 0–1; HR = 3.63, p < 0.001), EGFR exon 19 deletion (vs. L858R; HR = 0.50, p = 0.021), and liver involvement (HR = 2.65, p = 0.005) were associated with PFS on multivariable analysis. Discussion: EGFR aVAF was not associated with clinical outcomes. However, established prognostic factors including ECOG performance status, EGFR mutation subtype, and liver involvement were associated with PFS. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|